The RSV-Prem Study

What is RSV?

Respiratory Syncytial Virus (RSV) is a common virus that can cause serious respiratory illness in infants and young children. It is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in infants and young children, which can result in hospitalisation. Preterm infants are at particularly high risk of hospitalisation with an RSV infection. There are no vaccines available to prevent RSV infection. Currently there is a medication to prevent RSV, but it is usually reserved for infants who have serious heart or lung disease, and some premature infants born at less than 28 weeks gestation.

Purpose of the study

This study is being done to evaluate how effective a new medication (called MEDI8897) is at preventing serious respiratory illness caused by RSV in preterm infants.

Who can take part?

Healthy infants who were born preterm at 29 to 35 weeks and born from 1 July 2016.

What does the study involve?

  • Participation for approximately 1 year
  • 6 to 7 visits either at our study clinic, at Royal Children’s Hospital or in your home
  • 1 injection of the study medication or placebo (the same way that baby vaccines are given into the thigh)
  • 4 blood tests
  • Follow up of any respiratory illnesses that occur during this time

Who has approved the study?

This study has been approved by the Ethics Committees of The Royal Children’s Hospital Melbourne

Get involved

Study status: Recruiting in April and May 2017.
Who to contact for more information:
Please contact the study staff at the Vaccine and Immunisation Research Group
T | (03) 8344 9326
E | virgo-studies@unimelb.edu.au